4,000-Patient study aims to uncover hidden causes of heart valve disease
NCT ID NCT07065500
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is following 4,000 people with heart valve disease to look for new substances in the body (called metabolites) that might be linked to the disease. Researchers hope to find better ways to predict who will get worse and understand why. No new treatments are being tested—this is about gathering information to guide future research.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward new ways to predict or manage valvular heart disease.
- What could go wrong
- This is an observational study, not a treatment trial. It may identify risk factors but won't directly test a therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 4,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Mar 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients diagnosed with valvular heart disease during hospitalization were enrolled.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥18 years, gender is not limited. 2. Clinical diagnosis of heart valve disease (including aortic stenosis, aortic valve closure insufficiency due to different etiologies, mitral stenosis, mitral valve closure insufficiency, pulmonic stenosis, pulmonic valve closure insufficiency, tricuspid stenosis and tricuspid closure insufficiency due to different etiologies ) Exclusion Criteria: Patients unable to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Valvular heart disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The First Affiliated Hospital of Sun Yat-sen Univerity
RECRUITINGGuangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A soft patch that watches your heart beat in real time
- Can a blood test predict who recovers well from heart surgery?
- Prepping the body before heart surgery: could exercise shorten hospital stays?
- New flowchart could reduce ICU time and pacemakers after TAVR
- Nutrition check before heart surgery may flag lung risks in seniors
- AI-Powered patch could replace ultrasound for heart checkups